Home › Funds › Phocas Financial Corp. › AMRX
Phocas Financial Corp. position in AMRX
AMNEAL PHARMACEUTICALS INC · Health Care
Phocas Financial Corp. reported holding 819,476 shares of AMRX (AMNEAL PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$14.2M, representing 1.97% of its reported portfolio and ranking #2 among its reported holdings. Phocas Financial Corp. has disclosed AMRX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Phocas Financial Corp.'s AMRX position evolved
Phocas Financial Corp. first disclosed a stake in AMRX in Q4 2023 at 714,890 shares (US$4.3M). The position peaked in Q4 2025 at 1,282,974 shares, worth US$16.2M. Across 11 filings, Phocas Financial Corp. increased the stake 3 time(s), trimmed it 5 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 819,476 shares valued at US$14.2M — a reduction of -183,188 shares quarter over quarter.. Notable position changes include a 55% increase in Q2 2024 (shares rose 31% over the following quarter), a 31% increase in Q4 2024 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 714.89K | $4.34M | New |
| Q1 2024 | 697.08K | $4.22M | Reduce |
| Q2 2024 | 1.08M | $6.85M | Add |
| Q3 2024 | 1.02M | $8.45M | Reduce |
| Q4 2024 | 1.33M | $10.54M | Add |
| Q1 2025 | 1.26M | $10.55M | Reduce |
| Q2 2025 | 1.26M | $10.19M | Hold |
| Q3 2025 | 1.29M | $12.87M | Add |
| Q4 2025 | 1.28M | $16.17M | Hold |
| Q1 2026 | 1.00M | $12.46M | Reduce |
| Q2 2026 | 819.48K | $14.19M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AMRX and 13F data
AMRX (AMNEAL PHARMACEUTICALS INC) is a Health Care company. 47 other funds we track also report a position in AMRX — the largest reported positions include TPG GP A, LLC (US$213.4M), Rubric Capital Management LP (US$176.0M), Nantahala Capital Management, LLC (US$39.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AMRX
- TPG GP A, LLC 12.33M sh · $213.41M · Q2 2026
- Rubric Capital Management LP 10.17M sh · $176.02M · Q2 2026
- Nantahala Capital Management, LLC 2.27M sh · $39.27M · Q2 2026
- Westshore Wealth, LLC 1.37M sh · $23.65M · Q2 2026
- BlackBarn Capital Partners LP 1.30M sh · $22.50M · Q2 2026
- Penn Capital Management Company, LLC 1.18M sh · $20.48M · Q2 2026
- TUCKER ASSET MANAGEMENT LLC 1.01M sh · $17.50M · Q2 2026
More on Phocas Financial Corp.
FAQ
How long has Phocas Financial Corp. held AMRX?
Phocas Financial Corp. has disclosed AMRX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is Phocas Financial Corp.'s current position in AMRX?
As of Q2 2026, Phocas Financial Corp. holds 819.48K shares of AMRX (AMNEAL PHARMACEUTICALS INC), valued at $14.19M, representing 1.97% of its reported portfolio and ranking #2.
Has Phocas Financial Corp. been buying or selling AMRX?
In the latest 13F filing (Q2 2026), Phocas Financial Corp. reduced its position in AMRX. The position peaked in Q4 2025 at 1.28M shares.
Which other funds hold AMRX?
Other major institutional holders of AMRX include TPG GP A, LLC, Rubric Capital Management LP, Nantahala Capital Management, LLC, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.